GlassScriptPhysician profile
Kenneth K Chang
NPI 1134236821
$13,789.02
in general payments reported to CMS, 2019-2025
25 companies · $3,041 in 2025
The $3,041 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,996 · 2020: $312 · 2021: $723 · 2022: $2,235 · 2023: $1,868 · 2024: $2,615 · 2025: $3,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,680 · Long Term Medical Supply Or Device Loan: $838 · Travel and Lodging: $5.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,680.22 |
| Long Term Medical Supply Or Device Loan | $838.09 |
| Travel and Lodging | $5.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,149.53 | 2019-2025 | Unity, Hydrus Microstent, Clareon |
| Johnson & Johnson Surgical Vision, INC. | $2,605.07 | 2019-2024 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Sight Sciences, INC. | $1,000.41 | 2021-2025 | Omni Surgical System |
| Abbvie INC. | $893.64 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Bausch & Lomb Americas INC. | $720.44 | 2022-2025 | Envista Envy Iol, Envista Mx60 Iol, Envista Aspire Iol |
| Dompe US, INC. | $542.99 | 2022-2025 | Oxervate |
| Genentech USA, INC. | $528.97 | 2019-2024 | Vabysmo, Enspryng |
| New World Medical,INC. | $438.26 | 2023 | |
| Mallinckrodt Hospital Products INC. | $373.60 | 2021-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $368.04 | 2020-2025 | Eylea Hd, Eylea |
| Rxsight INC | $338.76 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Allergan, INC. | $326.91 | 2019-2022 | |
| Glaukos Corporation | $320.70 | 2019-2025 | Istent Trabecular Micro-Bypass System Model Is3, Istent Inject W, Photrexa Viscous and Photrexa |
| Oyster Point Pharma, INC. | $304.12 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $303.42 | 2024-2025 | Xdemvy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $303.39 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $270.84 | 2019-2024 | Cequa, Xelpros |
| Horizon Therapeutics Plc | $262.24 | 2021-2023 | Tepezza |
| Amgen INC. | $206.00 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $167.05 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $112.48 | 2024 | Syfovre |
| Alexion Pharmaceuticals, INC. | $98.92 | 2023-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $91.71 | 2019-2023 | |
| Harrow Eye, LLC | $42.16 | 2025 | Vevye |
| Kala Pharmaceuticals, INC. | $19.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.